Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:KROS

Keros Therapeutics Q3 2026 Earnings Date & Estimates

Keros Therapeutics logo
$11.33 +0.05 (+0.44%)
Closing price 04:00 PM Eastern
Extended Trading
$11.34 +0.01 (+0.04%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Keros Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for November 5, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Keros Therapeutics in Q3 2026

Keros Therapeutics is expected to post earnings of -$0.96 per share on revenue of $14.76 million. In the same quarter a year earlier Keros Therapeutics reported -$0.18 per share on revenue of $14.26 million. Keros Therapeutics last reported on August 3, 2026, posting -$1.45 per share and missing the -$1.34 consensus estimate. Keros Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.96
Expected Revenue
$14.76 million
Prior-Year EPS
-$0.18
Prior-Year Revenue
$14.26 million
Expected Revenue Growth
+3.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.45 (Missed by -$0.11)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Keros Therapeutics Q3 2026 Earnings FAQ

Keros Therapeutics (NASDAQ:KROS) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Keros Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Keros Therapeutics to post earnings of -$0.96 per share for Q3 2026.

The consensus revenue estimate for Keros Therapeutics is $14.76 million for Q3 2026.

Keros Therapeutics Earnings Headlines

Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Consensus Price Target of $20.50
October 24 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151781
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen
October 24 at 1:19 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151438
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.tc pixel
October 26 at 1:00 AM  |  Porter & Company (Ad)
Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play
September 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keros-therapeutics-advances-dmd-trial-for-ker-065-keeping-rare-disease-upside-in-play?utm_source=marketbeat.com&utm_medium=referral
Keros Therapeutics Expects $20 Million Milestone Payment From Takeda
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/keros-therapeutics-expects-20-million-143617749.html
Keros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 Trial
September 29, 2026  |  quiverquant.comQ
See More Keros Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Keros Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your email.

About Keros Therapeutics

Keros Therapeutics (NASDAQ:KROS) is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis. The company has also developed cibotercept (KER-012), an investigational therapy designed to modulate TGF-β family signaling for potential use in pulmonary arterial hypertension and other cardiovascular diseases.

Founded in 2015 and headquartered in Lexington, Massachusetts, Keros conducts research and clinical-development activities primarily in the United States, with clinical programs potentially involving international trial sites. The company is led by founder and Chief Executive Officer Jasbir Seehra. Keros has not marketed an approved commercial product, and its therapies remain subject to clinical testing and regulatory review.

View Keros Therapeutics Profile
Earnings Tools